We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years PR Newswire INDIANAPOLIS, Feb. 7, 2025 More than...
Drug manufacturer Eli Lilly (NYSE:LLY) announced today that Revenue in the fourth quarter rose 45% to $13.53 billion, driven by volume growth from Mounjaro and Zepbound, versus the consensus...
Lilly reports full Q4 2024 financial results and provides 2025 guidance PR Newswire INDIANAPOLIS, Feb. 6, 2025 Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions